Physician profile
Jade C Shaffer
NPI 1487128849
$4,469.11
in general payments reported to CMS, 2019-2025
17 companies · $24.24 in 2025
The $24.24 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $607 · 2022: $1,568 · 2023: $1,685 · 2024: $585 · 2025: $24.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,164 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,164.23 |
| Education | $130.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $796.67 | 2021-2025 | |
| Alkermes, INC. | $737.87 | 2021-2024 | Lybalvi, Aristada, Vivitrol |
| Janssen Pharmaceuticals, INC | $484.20 | 2021-2023 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $388.00 | 2022-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $319.20 | 2023-2024 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $293.99 | 2021-2023 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $261.21 | 2021-2023 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $250.00 | 2024 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $216.02 | 2021-2023 | |
| Indivior INC. | $158.30 | 2022-2023 | Perseris |
| Sunovion Pharmaceuticals INC. | $145.66 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $116.90 | 2021-2023 | Qelbree |
| Lundbeck LLC | $109.56 | 2021-2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $65.02 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.14 | 2021-2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $50.54 | 2022-2023 | Austedo Xr, Uzedy |
| Corium, LLC | $12.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jade Shaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.